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In a recent issue of Arthritis Research & Th  erapy, Gustaf-
sson and colleagues [1] presented the results of an 
interesting prospective study on risk factors for 
cardiovascular events (CVEs) in 182 Swedish patients 
with systemic lupus erythematosus (SLE) who were 
selected to be free of CVEs at inclusion. In contrast to the 
numerous cross-sectional studies and research on 
surrogate markers of cardiovascular disease (CVD) per-
formed, relatively few prospective studies on predictors 
of CVEs in SLE have been published [2-4]. In the present 
study, age, presence of any antiphospholipid antibody 
(aPL), von Willebrand factor (vWf), and absence of 
thrombocytopenia were independent predictors of the 
ﬁ  rst CVE.
Th  e study demonstrates the diﬃ   culties  inherent  in 
research of events in which the relative risk of the 
occurrence is high while the absolute risk of the event is 
low. Despite the improved overall survival in patients 
with SLE over the last decades, the risk for cardiovascular 
death has not diminished [5]. In female patients with 
SLE, the risk of myocardial infarction and stroke is 8- to 
10-fold greater than that of age-matched healthy women 
[6], and therefore the detection of predictors of these 
complications is of great importance. However, against 
the low background rate of CVEs in healthy, relatively 
young females, the absolute incidence rate of CVEs in 
lupus cohorts composed predominantly of females will 
be low. Gustafsson and colleagues report that 24 out of 
182 patients with SLE (mean age of 44 years; 90% of the 
patients were female) had at least one CVE after a mean 
follow-up of 8 years; this equates to the occurrence of 
one ﬁ  rst CVE in 63 patient-years. In the Lumina cohort, 
34 out of 546 patients developed at least one CVE after a 
median follow-up of 6 years (one ﬁ  rst CVE in 96 patient-
years) [2], and in the Toronto cohort, 118 out of 1,087 
patients had at least one arterial vascular event after an 
average follow-up of 9 years (one ﬁ  rst event in 83 patient-
years) [4]. Th   ese small absolute incidence rates illustrate 
the challenge of examining predictors of CVEs in SLE.
Another interesting issue is the association found 
between prothrombotic factors and endothelial activa-
tion and the occurrence of CVEs: vWf and the presence 
of any aPL were independent predictors of future CVEs 
in the Swedish patients with SLE [1]. As a marker of 
endothelial activation which promotes platelet adhesion 
and aggregation, vWf has been recognized as a predictor 
of cardiac events in other patient groups with pre-
existing vascular disease [7]. Moreover, increased vWf 
activity has been detected in SLE patients with subclinical 
atherosclerosis [8]. Release of vWf from endothelial cells 
can be induced by inﬂ  ammatory cytokines [7] but might 
also be triggered by immunologic factors, as suggested 
by Gustafsson and colleagues. Indeed, IgG from 
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Cardiovascular disease (CVD) has been identifi  ed as 
a major contributor to morbidity and mortality in 
patients with systemic lupus erythematosus (SLE). The 
etiology of premature CVD in SLE is supposed to have 
many factors, including traditional coronary artery 
disease (CAD) risk factors, antiphospholipid antibodies, 
and metabolic and infl  ammatory factors. Despite 
the overwhelming interest in CVD in SLE research, 
prospective studies evaluating risk factors for hard 
endpoints (that is, cardiovascular events) are relatively 
scarce. The article by Gustafsson and colleagues 
suggests that prothrombotic factors play an important 
role in SLE-related CVD and that the infl  uence of 
traditional CAD risk factors might be limited.
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demonstrated to induce the release of vWf [9], and in 
vitro, induction of vWf release by antibodies to double-
stranded DNA has been shown [10].
Remarkably, although several markers of systemic 
inﬂ  ammation (among others, high-sensitivity C-reactive 
protein) and markers of endothelial activation (vWf and 
soluble vascular cell adhesion molecule 1) were elevated 
at baseline in SLE patients who developed CVEs as 
compared with patients without CVEs, only the presence 
of vWf remained a signiﬁ  cant predictor in multivariable 
regression analysis [1]. In contrast, C-reactive protein 
serum levels at baseline predicted vascular events in the 
Lumina cohort [2].
Th  e presence of any aPL at baseline as a predictor of 
future vascular events has been reported from the 
Hopkins cohort [11] and the Lumina cohort [2] and is 
conﬁ   rmed by the Swedish study [1]. Th  e possible 
protective role of thrombocytopenia with respect to the 
occurrence of future CVEs, as reported by Gustafsson 
and colleagues, is a novel and interesting observation but 
this ﬁ  nding needs to be conﬁ  rmed in other studies. As 
discussed by the authors, the lack of association of 
traditional coronary artery disease risk factors, except 
age, might be explained by the limited number of patients 
and events in the study [1].
Another limitation of the present study might be the 
racial and ethnic background of the study population. 
Th   e great majority of the patients (94%) were Caucasians 
of European origin. Since racial and ethnic background 
inﬂ  uences disease severity and organ damage in patients 
with SLE, conﬁ   rmation of the results of the Swedish 
study in SLE cohorts with a signiﬁ  cantly diﬀ  erent racial 
and ethnic background in other parts of the world will be 
of great interest.
Despite more than three decades of research on the 
pathogenesis of CVD in SLE, the exact risk factors and 
the relative contribution of and interplay between 
thrombotic, atherosclerotic, and inﬂ  ammatory  factors 
are still under debate, and this hampers the development 
of intervention strategies to prevent CVEs in patients 
with SLE. Large-scale prospective studies performed by 
collaborating SLE research groups are needed to answer 
these important questions and to develop new 
intervention strategies based on measures that have been 
proven eﬀ  ective in the prevention of SLE-related CVD. 
Th  e next challenge will be the implementation of these 
prevention strategies in routine clinical practice.
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